Inhibition of Epstein-Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection.
Early events of human B-lymphocyte infection by Epstein-Barr virus involve the virus binding to CD21, capping, and subsequent internalization of the virus-receptor complex. We show here that alpha interferon (IFN-alpha) inhibits the capping of Epstein-Barr virus-CD21 complexes. Synthetic peptides with the CD21 binding motif of IFN-alpha mimic IFN-alpha activity, suggesting that this effect may be mediated by IFN-alpha-CD21 interaction. Our findings demonstrate a novel and immediate mechanism of IFN-alpha action.
California Institute of Biological Research, La Jolla.
A X
AX
Delcayre
M
M
Lotz
W
W
Lernhardt
D001402:B-Lymphocytes / Q000382:microbiology*; D001667:Binding, Competitive; D004854:Herpesvirus 4, Human / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000494:pharmacology*; D010446:Peptide Fragments / Q000494:pharmacology*; D017464:Receptors, Complement 3d / Q000276:immunology / Q000378:metabolism*
D016898:Interferon-alpha; D010446:Peptide Fragments; D017464:Receptors, Complement 3d